In clinical practice, patients with low and positive HER2 expression generally have higher tumor grades, larger tumors, more lymph node metastases [41], a smaller percentage of lobular carcinomas [42], and an increased risk of brain metastases [43]. Here, ERBB2 is linked to neoplasm.